耀才团队: 恒指能否重上250天线将成关键
耀才研究部称,上周五(10日)美股三大指数上升,虽然美国疫情至今仍未有改善,但药厂研发应付疫情的药物瑞德西伟疫苗测试结果正面,利好美股市场气氛,而银行股带动市况上升,令道指升幅较大。港股ADR普遍上升,「黑期」预示恒指今早将上升近200点左近,而美元兑离岸人民币再度下试7算水平,人民币强势有利股市短期後市表现。
港汇方面,上周五港汇一度转弱,但整体而言仍贴近「强方兑换保证」7.75水平,金管局短期会否再需要承接港元买盘将是关键,只要短期後市仍维持有热钱流入,港股仍有条件再向上破顶。因此,港股日均成交金额於短期後市能否维持接近2,000亿港元水平左近将成关键。
从技术上看,恒指上周五再度跌穿250天线,目前250天线暂在26,053点。但如前文所述,只要恒指仍企稳於6月10日高位25,303点之上,投资者短期後市仍不宜过分看淡,在整固过後,指数仍有条件重上250天线并再创月内新高。
(笔者为证监会持牌人)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.